Open Accessil 28B polymorphisms and the prognosis for the efficacy of antiviral therapy in viral hepatitis C patients in Uzbekistan
Author(s) -
Dildora Sekler,
Секлер Д. Э,
Dinara Khudayberganova,
Худайберганова Д. М,
Р. Р. Латыпов,
Латыпов Р. Р,
Г. З. Усманова,
Усманова Г. З,
Mirzokhid Rakhmanov,
Рахманов М. И,
Erkin Musabaev,
Мусабаев Э. И
Publication year - 2014
Publication title -
èpidemiologiâ i infekcionnye bolezni
Language(s) - English
Resource type - Journals
eISSN - 2411-3026
pISSN - 1560-9529
DOI - 10.17816/eid40843
Subject(s) - genotyping , single nucleotide polymorphism , snp , virology , snp genotyping , peripheral blood mononuclear cell , biology , hepatitis c virus , gene , taqman , population , immunology , genotype , medicine , virus , genetics , polymerase chain reaction , environmental health , in vitro
By means of the Association for the Study of complete genome there was identified the prognostic value of polymorphisms associated with single-nucleotide substitutions (SNP) in the human genome and located in the region of the gene IL28B/IFN-L3. Hereafter also there were identified SNP in the gene IFN-L4 and there was found a correlation between the population and the spontaneous elimination of HCV infection. Methods: In the studies there was used the materialfrom 135 HCV-infected persons residing on the territory of Uzbekistan. DNA was isolated from peripheral blood mononuclear cells (PBMC), then SNP genotyping of the IFN-L3 gene region (rs8099917, rs12979860) was performed by means of three methods: Invader Plus Assay, TaqMan Assay and direct sequencing. The plot of the IFN-L4 gene (ss469415590) was sequenced. Results: Out of the 135 studied patients, who received antiviral treatment according to the standard scheme Peg-IFN-a in combination with RBVfor 24 and 48 weeks, 87,4% were belonged to the Central Asian (CA) ethnic group and 12.6% - Eastern European (EE). Among the examined cases, there no virological response to antiviral therapy was observed in 21.2% of patients from CA group and 35.3% of EE patients (p